新华制药(000756.SZ)：帕拉米韦注射液上市许可持有人转让申请获得批准

智通财经网04-08

新华制药(000756.SZ)发布公告，2023年3月，新华制药与苏州爱美津签订了帕拉米韦注射液(15ml：0.15g)的生产技术及持有人转让合同，合同约定苏州爱美津通过变更上市许可持有人至新华制药，新华制药最终成为本品的上市许可持有人，并享有相关权益，包括但不限于产品生产技术、销售、市场推广等。近日，公司收到国家药品监督管理局核准签发的帕拉米韦注射液(15ml：0.15g)《药品补充申请批准...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2425950424?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-04-08 17:02","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2425950424","market":"other","top_or_hot":-1,"title":"新华制药(000756.SZ)：帕拉米韦注射液上市许可持有人转让申请获得批准","media":"智通财经网","content":"<div>\n<p>新华制药(000756.SZ)发布公告，2023年3月，新华制药与苏州爱美津签订了帕拉米韦注射液(15ml：0.15g)的生产技术及持有人转让合同，合同约定苏州爱美津通过变更上市许可持有人至新华制药，新华制药最终成为本品的上市许可持有人，并享有相关权益，包括但不限于产品生产技术、销售、市场推广等。近日，公司收到国家药品监督管理局核准签发的帕拉米韦注射液(15ml：0.15g)《药品补充申请批准...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-08/doc-inarchuw3275214.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>新华制药(000756.SZ)：帕拉米韦注射液上市许可持有人转让申请获得批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n新华制药(000756.SZ)：帕拉米韦注射液上市许可持有人转让申请获得批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-08 17:02 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-08/doc-inarchuw3275214.shtml><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>新华制药(000756.SZ)发布公告，2023年3月，新华制药与苏州爱美津签订了帕拉米韦注射液(15ml：0.15g)的生产技术及持有人转让合同，合同约定苏州爱美津通过变更上市许可持有人至新华制药，新华制药最终成为本品的上市许可持有人，并享有相关权益，包括但不限于产品生产技术、销售、市场推广等。近日，公司收到国家药品监督管理局核准签发的帕拉米韦注射液(15ml：0.15g)《药品补充申请批准...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-08/doc-inarchuw3275214.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0164","symbol_name":"国企混改","start_time":0,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-08/doc-inarchuw3275214.shtml","article_id":"2425950424","we_media_id":null,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-08/doc-inarchuw3275214.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2425950424","pubTimestamp":1712566920,"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"新华制药发布公告，2023年3月，新华制药与苏州爱美津签订了帕拉米韦注射液的生产技术及持有人转让合同，合同约定苏州爱美津通过变更上市许可持有人至新华制药，新华制药最终成为本品的上市许可持有人，并享有相关权益，包括但不限于产品生产技术、销售、市场推广等。近日，公司收到国家药品监督管理局核准签发的帕拉米韦注射液《药品补充申请批准通知书》，该产品上市许可持有人转让申请获得批准。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK0164":"国企混改","000756":"新华制药","BK0239":"医药制造"},"translate_title":"Xinhua Pharmaceutical (000756. SZ): The transfer application of paramivir injection marketing license holder was approved","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"000756":1},"content_text":"新华制药(000756.SZ)发布公告，2023年3月，新华制药与苏州爱美津签订了帕拉米韦注射液(15ml：0.15g)的生产技术及持有人转让合同，合同约定苏州爱美津通过变更上市许可持有人至新华制药，新华制药最终成为本品的上市许可持有人，并享有相关权益，包括但不限于产品生产技术、销售、市场推广等。近日，公司收到国家药品监督管理局核准签发的帕拉米韦注射液(15ml：0.15g)《药品补充申请批准通知书》，该产品上市许可持有人转让申请获得批准。据悉，帕拉米韦是新一代神经氨酸酶抑制剂，可选择性地抑制人甲型和乙型流感病毒的神经氨酸酶，抑制成熟的流感病毒脱离宿主细胞，达到抑制流感病毒在人体内的传播，以起到治疗流行性感冒的作用，主要用于治疗甲型或乙型流行性感冒。\n\n股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2425950424"}